Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L. Gori S, et al. Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7. Eur J Cancer. 2018. PMID: 29886394 Review.
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research. Colozza M, et al. Among authors: gori s. Clin Breast Cancer. 2005 Aug;6(3):253-9. doi: 10.3816/cbc.2005.n.028. Clin Breast Cancer. 2005. PMID: 16137437
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with Regional Sections (2007-2009). Gori S, et al. Tumori. 2010 Nov-Dec;96(6):1010-5. Tumori. 2010. PMID: 21388067
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M. Del Mastro L, et al. Among authors: gori s. JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991. JAMA. 2011. PMID: 21771987 Clinical Trial.
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group "Interactions with Regional Sections" (2009-2011). Gori S, et al. Tumori. 2011 Jul-Aug;97(4):442-8. doi: 10.1177/030089161109700405. Tumori. 2011. PMID: 21989431
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Pestrin M, et al. Among authors: gori s. Breast Cancer Res Treat. 2012 Jul;134(1):283-9. doi: 10.1007/s10549-012-2045-1. Epub 2012 Apr 4. Breast Cancer Res Treat. 2012. PMID: 22476856 Clinical Trial.
433 results